Adlai Nortye Group Ltd. (ANL) stock
ANLNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới năm tài chính 2025, năm kết thúc ngày Dec 31, 2025Last filing: 20-F on Apr 10, 2026Score 0/30
$8.74−0.74 (-7.81%)
Close on Nov 18, 2026Market cap $349.60MP/E –Yield –
Adlai Nortye r&d expenses
Research and development expenses are spending on new products and technology.
For fiscal 2025 it was $32.83M, down 26.9% from the year before. The highest annual figure on record is $58.15M in fiscal 2023.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $32.83M | -26.9% |
| FY2024 | Dec 31, 2024 | $44.92M | -22.8% |
| FY2023 | Dec 31, 2023 | $58.15M | +6.7% |
| FY2022 | Dec 31, 2022 | $54.49M | +29.4% |
| FY2021 | Dec 31, 2021 | $42.11M | – |
See a number that looks wrong?